CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19

CAR-T company Arcellx Inc ACLX priced its IPO at $15 per share, raising $123.8 million at the low end of the Company’s proposed range of $15 - $17.

  • The Company offered 8.3 million shares during the initial public offering.
  • Arcellx's lead ddCAR candidate, CART-ddBCMA, is in Phase 1 development for relapsed or refractory (r/r) multiple myeloma (MM). 
  • Arcellx plans to initiate a Phase 2 trial of CART-ddBCMA for treatment of r/r MM in late 2022 and pursue the development of the candidate in earlier lines of therapy.
  • In 2020, the Company showed its lead BCMA-targeting CAR-T for multiple myeloma shrunk tumors in six out of six patients, with four of them experiencing a stringent complete response.
  • The latest results, presented at ASH last year, showing 19 out of 19 patients saw their tumors shrink, with 13 seeing a stringent complete response. Sixteen patients were still responding after 21 months.
  • Arcellx will list on the NASDAQ under the symbol ACLX. 
  • BofA Securities, SVB Leerink, Barclays, and William Blair acted as joint bookrunners on the deal.
  • Price Action: ACLX shares opened for trade at $19.
Loading...
Loading...
ACLX Logo
ACLXArcellx Inc
$57.137.91%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
26.75
Growth
-
Quality
-
Value
13.71
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...